The use of fragment-based drug discovery to develop novel small molecules that modulate the BRCA2-RAD51 interaction for the treatment of cancer

Projektinformationen

BRCA2-RAD51

ID Finanzhilfevereinbarung: 274569

Projekt abgeschlossen

Startdatum 1 März 2011

Enddatum 28 Februar 2013

Finanziert unter

• Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)

Gesamtkosten € 201 049,60

EU-Beitrag € 201 049,60

Koordiniert durch

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom